AbbVie Inc. $ABBV Shares Sold by Eastern Bank

Eastern Bank cut its stake in AbbVie Inc. (NYSE:ABBV) by 15.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 318,655 shares of the company’s stock after selling 56,180 shares during the quarter. AbbVie makes up approximately 1.2% of Eastern Bank’s portfolio, making the stock its 23rd largest holding. Eastern Bank’s holdings in AbbVie were worth $80,186,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of ABBV. Ranch Capital Advisors Inc. boosted its stake in AbbVie by 37.0% during the first quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock worth $3,238,000 after buying an additional 4,017 shares during the last quarter. Calamos Advisors LLC grew its holdings in AbbVie by 3.4% in the 4th quarter. Calamos Advisors LLC now owns 466,290 shares of the company’s stock valued at $106,543,000 after buying an additional 15,458 shares in the last quarter. Bingham Private Wealth LLC acquired a new stake in shares of AbbVie in the 4th quarter worth $1,147,000. Axecap Investments LLC increased its stake in shares of AbbVie by 713.2% in the 4th quarter. Axecap Investments LLC now owns 16,320 shares of the company’s stock worth $3,729,000 after acquiring an additional 14,313 shares during the last quarter. Finally, Robinhood Asset Management LLC purchased a new position in shares of AbbVie during the 4th quarter worth $15,781,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Trading Down 2.5%

NYSE ABBV opened at $244.62 on Tuesday. The stock has a market cap of $432.19 billion, a PE ratio of 69.10, a P/E/G ratio of 0.83 and a beta of 0.30. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $267.47. The stock has a fifty day simple moving average of $239.67 and a 200-day simple moving average of $224.25.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 466.39%. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same period in the previous year, the firm earned $2.97 EPS. AbbVie’s revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts predict that AbbVie Inc. will post 14.12 EPS for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

Wall Street Analysts Forecast Growth

ABBV has been the topic of several recent research reports. HSBC reissued a “buy” rating and set a $300.00 price target on shares of AbbVie in a research report on Monday, July 6th. Guggenheim lifted their target price on shares of AbbVie from $249.00 to $261.00 and gave the stock a “buy” rating in a research note on Thursday, July 9th. Royal Bank Of Canada boosted their target price on shares of AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a report on Friday, July 10th. Wells Fargo & Company increased their price target on shares of AbbVie from $260.00 to $295.00 and gave the company an “overweight” rating in a research note on Friday, July 10th. Finally, Citigroup raised their price target on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $271.48.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported strong second-quarter results, with revenue up 10.2% year over year and adjusted earnings per share exceeding consensus estimates. Growth from Skyrizi, Rinvoq and neuroscience products helped offset the continuing decline of Humira. AbbVie: Strong Q2 And New Catalysts Keep Me Bullish
• Positive Sentiment: Cantor Fitzgerald raised its AbbVie price target from $265 to $285 and maintained an “overweight” rating, reflecting confidence in the company’s growth outlook and pipeline.
• Positive Sentiment: New oncology opportunities could provide additional long-term growth. AbbVie’s telisotuzumab adizutecan is cited as an emerging targeted treatment in esophageal cancer, while the late-stage ABBV-706 trial is testing another potential therapy in small-cell lung cancer. Esophageal Cancer Market Outlook
• Neutral Sentiment: Analyst commentary remains broadly constructive, with some estimates suggesting shares could approach $300, supported by AbbVie’s dividend profile and the performance of newer growth products. AbbVie Quietly Solved Its Biggest Problem—Now What?
• Negative Sentiment: The Apogee Therapeutics acquisition is reducing projected 2026 earnings per share while increasing research and development costs. Although AbbVie raised its revenue outlook, the earnings dilution and weaker near-term guidance have prompted investor caution. ABBV Q2 Earnings Call Balances Growth With Apogee Dilution

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.